Evidence map›Paper›PMID 41748875›Full record

ArticleScientific reports2026

Novel magnetically retrievable SnO

Akbar Hussain, Saptarshi Roy, Md Ahmaruzzaman

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Akbar HussainDepartment of Chemistry, National Institute of Technology Silchar, Silchar, Assam, 788010, India.
Saptarshi RoyDepartment of Chemistry, National Institute of Technology Silchar, Silchar, Assam, 788010, India.
Md AhmaruzzamanDepartment of Chemistry, National Institute of Technology Silchar, Silchar, Assam, 788010, India. mda2002@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Wastewater effluents are known to contain a diverse range of organic contaminants, among which pharmaceutical residues constitute a significant and persistent fraction. The escalating global challenge of antimicrobial resistance highlights the urgent need for innovative and sustainable remediation strategies. In this context, the present study reports the rational design and fabrication of a ternary SnO2/Fe3O4/WSe2 (SFW) heterostructure via a hydrothermal synthesis route. The incorporation of Fe3O4 endows the composite with magnetic properties, facilitating facile recovery and recyclability via an external magnetic field, whereas SnO2 contributes strong oxidative potential and high electron mobility. Meanwhile, WSe2, a narrow-bandgap semiconductor, enhances visible-light harvesting and promotes efficient charge transfer, thereby enhancing the overall photocatalytic activity of the SFW nanocomposite. The photocatalytic performance of the synthesized SFW catalyst was systematically evaluated through the degradation of tinidazole (TNZ) under visible-light irradiation, achieving an impressive degradation efficiency of 89.28% within 60 min under optimized conditions. The influence of critical operational parameters, such as catalyst dosage, H2O2 concentration, and initial pollutant load, was systematically investigated to establish the optimal degradation conditions. Additionally, the degradation pathway was proposed based on the VB-XPS analysis and reactive oxygen species (ROS) identification via scavenging assays. The effect of coexisting ions, other pharmaceuticals, and different water matrices was also examined to assess the environmental applicability of the catalyst. Notably, the inclusion of Fe3O4 markedly enhanced the magnetic recoverability of the photocatalyst over the subsequent catalytic runs, significantly enhancing the practicality of the SFW system for real-world wastewater treatment applications.

Indexed as

HeterojunctionMagneticPharmaceuticalsPhotodegradationReusabilityTinidazole

Identifiers

PMID41748875
PMCPMC13046952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.